The next ACAD.
Get in today under a dime.
Patented MANF technology could be worth billions.
Partnership news is imminent according to the company's C.E.O.
AMBS at this point is a pump and dump . . . good at publishing white papers and attending conferences. May be something in the future, but they have no money. There is plenty of time to get into this company, if they can actually survive.
My goodness, only 4 cents?
The company is sponsoring the NFL Head Injury symposium to be held later this month in Minneapolis.
After I sell my ACAD shares i might buy that company.